- Jefferies is out with some commentary on Opko Health (OPK +5.2%) amid controversy surrounding a short thesis advanced by Lakewood Capital (see Lakewood's article on SA here).
- "In our view, timely achievements of its laid-out milestones and future sales revenues meeting our expectations (albeit significantly lower than its noted market opportunities) would likely provide potential upside to current levels," analyst Eun Yang says.
- Buy rating reiterated.
- Price target is $11.50.
Jefferies still bullish on Opko despite short call
From other sites
at CNBC.com (Dec 31, 2014)
at CNBC.com (Dec 22, 2014)
at CNBC.com (Dec 15, 2014)
at CNBC.com (Nov 7, 2014)
at CNBC.com (Oct 15, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs